{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zarranz-Ventura J"],"funding":["Roche (F. Hoffmann-La Roche Ltd)","Roche"],"pagination":["3306-3313"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12669756"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["39(18)"],"pubmed_abstract":["<h4>Background</h4>To evaluate treatment intervals at 12/24 months following initiation of anti-VEGF therapy and to characterise the clinical profile of neovascular AMD (nAMD) patients achieving extended treatment intervals (≥12 and ≥16 weeks).<h4>Methods</h4>National, retrospective, real-world study using data from the validated web-based Fight Retinal Blindness (FRB!) registry. Treatment-naive nAMD eyes managed with approved first-generation intravitreal VEGF inhibitors (ranibizumab, aflibercept 2 mg) and followed for at least 12 months were included. A subanalysis was conducted on eyes receiving a number of injections within range of a treat and extend (TAE) regimen at 12 and 24 months.<h4>Results</h4>A total number of 1278/557 treatment-naïve nAMD eyes within the TAE range category com"],"journal":["Eye (London, England)"],"pubmed_title":["Treatment intervals with first-generation anti-vascular endothelial growth factor drugs: evaluating the unmet need in a real-world neovascular age-related macular degeneration national database."],"pmcid":["PMC12669756"],"funding_grant_id":["Independent research collaboration"],"pubmed_authors":["Carreno E","Castillon Torre LJ","Parrado-Carrillo A","Perez Rivases G","Catalan Munoz P","Lorenzo Parra D","Chinchurreta Capote A","Carnota-Mendez P","Del-Barrio-Lopez-de-Ipina Z","Sanchez J","Gonzalez Guijarro J","Abraldes Lopez-Veiga MJ","Gomez A","Alonso E","Carrillo S","Garcia Zamora M","Arnaiz P","Gismero-Moreno S","Casaroli-Marano RP","Vega-Gonzalez R","Gallego-Pinazo R","Cobos E","Diaz-de-Durana-Santa-Coloma E","Montejano-Milner R","Hernandez-Martinez A","Fernandez-Robredo P","Pareja Esteban J","Zarranz-Ventura J","Munoz Sanz N","Belmonte Grau M","Cilveti E","Ruiz Moreno JM","Galletero L","Garcia-Lunar P","Rodriguez-Cid MJ","Serrano A","Miguel-Escuder L","Alarcon-Valero I","Cobo-Soriano R","Torres-Borrego C","Acebes Garcia M","Lavid de Los Mozos FJ","Garrido M","Sanchez-Vela L","Figueroa MS","Gomez-Moreno A","Tena Sempere ME","Brosa H","Fernandez Varela P","Broc-Iturralde L","Dolz-Marco R","Espineira Perinan MA","Honrubia Grijalbo A","Londono G","Rodriguez Hurtado F","Arias-Barquet L","Martin-Pinardel R","Mantrana Bermejo ME","Valldeperas X","Ascaso-Puyuelo FJ","Flores-Moreno I","Rodriguez-Fernandez CA","Castro Casal N","Boned Murillo A","de Fatima Alvarez Gil M","Salinas Martinez E","Garay-Aramburu G","Grau J","Olivera M","Herrero-Diaz I","Quintero Gonzalez C","Pinas Garcia P","Moreno Gutierrez JA","Bernal-Morales C","Rodriguez-Feijoo D","Vilaplana Mira F","Mendez-Vazquez C","Ventura N","Rethati C","Saenz de Viteri M","Fernandez-Hortelano A","Garcia-Martinez JR","Sararols-Ramsay L","Aparicio Sanchis S","Campos Figueroa P","Marias-Perez S","Rubio Cid S","Izquierdo-Serra J","Banon K","Bakkali El Bakkali I","Azrak Haskour C","Zapata MA","Arrazola Berrizbeitia MT","Diago T","Pina-Marin B","Batlle-Ferrando S","Calvo P","Ruiz-Moreno O","Cacelliere Fernandez J","Ciancas E","Fonollosa Calduch A","Larrauri-Arana A","Alforja S","Figueras-Roca M","Velazquez-Villoria D","Garcia-Arumi J","Moll-Udina A","Sanchez JA","Barnes C","Fernandez-Bonet M","Rodriguez-Maqueda M","Garcia-Layana A","Asencio Duran M","Zarallo-Gallardo J","Lozano-Escobar I","Moreno-Martin P","Escobar-Barranco JJ","Cholbi M","FRB SPAIN study group","Arruabarrena C","Gomez Sanchez S","Diaz Barreda MD","Ruiz-Del-Tiempo MP","Pinero Sanchez A","Gomez Conde ML","Rodriguez-Nunez M","Puzo M","Gonzalez Escobar AB","Fernandez Rodriguez MI","Sotomayor Toribio M","Campo Gesto A","Gonzalez-Lopez JJ","Oliver N","Aldazabal-Echeveste M","Recalde S","Liano-Sanz Diez de Ulzurrun G"],"additional_accession":[]},"is_claimable":false,"name":"Treatment intervals with first-generation anti-vascular endothelial growth factor drugs: evaluating the unmet need in a real-world neovascular age-related macular degeneration national database.","description":"<h4>Background</h4>To evaluate treatment intervals at 12/24 months following initiation of anti-VEGF therapy and to characterise the clinical profile of neovascular AMD (nAMD) patients achieving extended treatment intervals (≥12 and ≥16 weeks).<h4>Methods</h4>National, retrospective, real-world study using data from the validated web-based Fight Retinal Blindness (FRB!) registry. Treatment-naive nAMD eyes managed with approved first-generation intravitreal VEGF inhibitors (ranibizumab, aflibercept 2 mg) and followed for at least 12 months were included. A subanalysis was conducted on eyes receiving a number of injections within range of a treat and extend (TAE) regimen at 12 and 24 months.<h4>Results</h4>A total number of 1278/557 treatment-naïve nAMD eyes within the TAE range category com","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-05T20:37:59.08Z","creation":"2026-05-21T03:12:52.153Z"},"accession":"S-EPMC12669756","cross_references":{"pubmed":["41102554"],"doi":["10.1038/s41433-025-03996-8"]}}